Inclusion Criteria:

          1. Histologically confirmed diagnosis of adenocarcinoma of the prostate, renal cell
             carcinoma or urothelial carcinoma. Small cell or neuroendocrine tumors of the prostate
             are also permitted.

          2. Radiographic evidence of at least one bone, lymph node, soft tissue, or liver
             metastasis, that is amenable to iodinated contrast injection, as judged by the study
             radiologist

          3. Adequate laboratory values:

               1. Platelets ≥ 100,000

               2. INR ≤ 1.3

          4. Age > 18 years.

          5. Ability to understand and the willingness to sign a written informed consent document.

        Exclusion Criteria:

          1. History of intercurrent or past medical or psychiatric illness that would make
             participation in a research biopsy protocol difficult or not feasible at the
             discretion of the principal investigator or co-investigator(s).

          2. Cr >2.0

          3. History of iodinated contrast allergy

          4. For patients undergoing research only biopsy: Requirement for anticoagulation with
             heparin, low molecular weight heparin, clopidogrel, rivaroxaban, dabigatran, apixaban,
             warfarin, Aggrenox, fondaparux, ticagrelor, etc (aspirin and other NSAIDs are ok but
             should be held prior to biopsy in accordance with institutional standard of care)

          5. Any other contraindication to CT with iodinated contrast, as CT with contrast will be
             used in the study.